A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine (13vPnC) and 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Pneumococcal Infections, sponsored by Pfizer. Completed at 26 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-15.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 2nd largest by enrollment, is one of 6 that started in 2007, is one of 19 in phase 3, and was the 2nd registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 20 · Phase 4 11
First in 2004; this study’s year is marked. 6 started in 2007.
This study's enrollment of 2,141 is above the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 328 across the 44 interventional studies. Of the 40 that completed or were terminated, 23 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 6th largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2007, is one of 33 in phase 3, and was the 7th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety, tolerability and immune response of 13-valent pneumococcal conjugate vaccine (13vPnC) compared with 23-valent Pneumococcal Polysaccharide Vaccine (23vPS). Although the study started with only 1 population, amendments to the original protocol will now reflect three participant populations. Three age cohorts will be enrolled. The first cohort (age 60-64) will be blinded. Cohort 2 (age 50-59) and cohort 3 (age 18-49) are open label. Subjects in cohorts 1 and 2 will receive 2 vaccinations 3-4 years apart. Subjects in cohort 3 will receive 1 vaccination. All participants should be naïve of 23vPS. Comparisons of immune responses from the different cohorts will be done.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)
Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
Participants aged 50-59 years given a 0.5 mL dose administered on day 1.
Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)
Participants aged 18-49 years given a 0.5 mL dose administered on day 1.
Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)
Participants aged 60-64 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)
Participants aged 60-64 years who received 23vPS at vaccination 1 receive a 0.5 mL dose of 23vPS administered 3-4 years after dose 1.
Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
Participants aged 50-59 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)
0.5 mL dose administered on day 1
0.5 mL dose administered on day 1
0.5 mL dose administered on day 1
0.5 mL dose administered on day 1
0.5 mL dose administered 3-4 years after dose 1
0.5 mL dose administered 3-4 years after dose 1
0.5 mL dose administered 3-4 years after dose 1
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination 1
Serotype-specific OPA GMTs for the 13 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using microcolony OPA (mcOPA) assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: One month after vaccination 1
Percentage of Participants Achieving At Least a 4-fold Rise in OPA Titer for Serotype 6A 1 Month After Vaccination 1 in Cohort 1
For serotype 6A the percentage of participants achieving at least a 4-fold rise on the serotype-specific antibody titer from pre-vaccination to 1 month post-vaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.
Time frame: One month after vaccination 1
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination for 12 Common Serotypes in 13vPnC/23vPS Group Relative to 23vPS Group and 23vPS/23vPS Group
Serotype-specific OPA GMTs for the 12 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using mcOPA assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: One month after vaccination 1 and One month after vaccination 2/Year 3 to 4
Percentage of Participants Achieving OPA Titers With at Least Lower Limit of Quantification (LLOQ) 1 Month After Vaccination 1
Percentage of participants achieving OPA GMTs with at least LLOQ for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of all participants using mcOPA assay. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=1:18, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.
Time frame: One month after vaccination 1
Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes From Prevaccination 1 to 1 Month After Vaccination 2 in Cohort 1 and Cohort 2
Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
Time frame: Prevaccination 1 to 1 month after vaccination 2/Year 3 to 4
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) for 12 Common Serotypes in 13vPnC/23vPS Group Relative to 23vPS and 23vPS/23vPS Groups in Cohort 1; and in 13vPnC/13vPnC Group in Cohort 2, 1 Month After Vaccination
Antibody geometric mean concentration (GMC) as measured by microgram/milliliter (mcg/mL) for 12 common pneumococcal serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
Time frame: One month after vaccination 1 and One month after vaccination 2/Year 3 to 4
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 2 (Year 3 to 4) in Cohort 1 and Cohort 2
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 cm; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).
Time frame: Within 14 days after vaccination 2
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 2 (Year 3 to 4) in Cohort 1 and Cohort 2
Systemic events reported using an electronic diary. Systemic events are any fever \>=38 degrees C, fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain, aggravated generalized muscle pain , new generalized joint pain), and aggravated generalized joint pain.
Time frame: Within 14 days after vaccination 2
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 1
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation \[lim\] present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).
Time frame: Within 14 days after vaccination 1
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 1
Systemic events reported using an electronic diary. Systemic events are any fever greater than or equal to (\>=) 38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized (gen) muscle pain, aggravated generalized muscle pain , new generalized joint pain), and aggravated generalized joint pain. All reports of fever \>40 degrees C in 13vPnC and 23vPS for Cohort 1 were confirmed as data entry errors.
Time frame: Within 14 days after vaccination 1
| Milestone | 13vPnC, Cohort 1 | 23vPS, Cohort 1 | 13vPnC, Cohort 2 | 13vPnC, Cohort 3 | 13vPnC/13vPnC, Cohort 1 | 13vPnC/23vPS, Cohort 1 | 23vPS/23vPS, Cohort 1 | 13vPnC/13vPnC, Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 411 | 411 | 392 | 854 | 0 | 0 | 0 | 0 |
| Completed | 411 | 411 | 392 | 502 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 352 | 0 | 0 | 0 | 0 |
| Withdrew: Did not enter 1-year blood draw | 0 | 0 | 0 | 352 | 0 | 0 | 0 | 0 |
| Milestone | 13vPnC, Cohort 1 | 23vPS, Cohort 1 | 13vPnC, Cohort 2 | 13vPnC, Cohort 3 | 13vPnC/13vPnC, Cohort 1 | 13vPnC/23vPS, Cohort 1 | 23vPS/23vPS, Cohort 1 | 13vPnC/13vPnC, Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 108 | 108 | 189 | 214 |
| Completed | 0 | 0 | 0 | 0 | 107 | 108 | 189 | 212 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Failed to return | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | 13vPnC, Cohort 1 | 23vPS, Cohort 1 | 13vPnC, Cohort 2 | 13vPnC, Cohort 3 | 13vPnC/13vPnC, Cohort 1 | 13vPnC/23vPS, Cohort 1 | 23vPS/23vPS, Cohort 1 | 13vPnC/13vPnC, Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 418 | 417 | 406 | 900 | 0 | 0 | 0 | 0 |
| Vaccinated | 417 | 414 | 404 | 899 | 0 | 0 | 0 | 0 |
| Completed | 411 | 411 | 392 | 854 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 6 | 14 | 46 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 4 | 32 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 4 | 0 | 3 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 4 | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Failed to return | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized, not vaccinated | 1 | 3 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Milestone | 13vPnC, Cohort 1 | 23vPS, Cohort 1 | 13vPnC, Cohort 2 | 13vPnC, Cohort 3 | 13vPnC/13vPnC, Cohort 1 | 13vPnC/23vPS, Cohort 1 | 23vPS/23vPS, Cohort 1 | 13vPnC/13vPnC, Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 411 | 411 | 392 | 502 | 0 | 0 | 0 | 0 |
| Completed | 404 | 396 | 373 | 469 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 15 | 19 | 33 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 5 | 2 | 21 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 3 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 6 | 5 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Failed to return | 0 | 0 | 12 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Milestone | 13vPnC, Cohort 1 | 23vPS, Cohort 1 | 13vPnC, Cohort 2 | 13vPnC, Cohort 3 | 13vPnC/13vPnC, Cohort 1 | 13vPnC/23vPS, Cohort 1 | 23vPS/23vPS, Cohort 1 | 13vPnC/13vPnC, Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 404 | 396 | 373 | 469 | 0 | 0 | 0 | 0 |
| Completed | 216 | 189 | 214 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 188 | 207 | 159 | 469 | 0 | 0 | 0 | 0 |
| Withdrew: Did not consent to receive vax 2 | 188 | 207 | 159 | 469 | 0 | 0 | 0 | 0 |
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 cm; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).
| Percentage of participants | 13vPnC/13vPnC, Cohort 1 | 23vPS/23vPS, Cohort 1 | 13vPnC/23vPS, Cohort 1 | 13vPnC/13vPnC, Cohort 2 |
|---|---|---|---|---|
| Redness: Any | 20.0 (10.0 to 33.7) | 35.8 (26.8 to 45.5) | 27.5 (15.9 to 41.7) | 21.4 (13.2 to 31.7) |
| Redness: Mild | 20.0 (10.0 to 33.7) | 27.7 (19.3 to 37.5) | 22.4 (11.8 to 36.6) | 18.1 (10.5 to 28.0) |
| Redness: Moderate | 6.3 (1.3 to 17.2) | 18.7 (11.3 to 28.2) | 11.4 (3.8 to 24.6) | 5.3 (1.5 to 13.1) |
| Redness: Severe | 0.0 (0.0 to 7.5) | 10.6 (5.0 to 19.2) | 2.4 (0.1 to 12.6) | 1.4 (0.0 to 7.4) |
| Swelling: Any | 24.5 (13.8 to 38.3) | 35.6 (26.4 to 45.6) | 20.4 (10.2 to 34.3) | 22.6 (14.2 to 33.0) |
| Swelling: Mild | 21.2 (11.1 to 34.7) | 20.9 (13.1 to 30.7) | 18.8 (8.9 to 32.6) | 21.4 (13.2 to 31.7) |
| Swelling: Moderate | 10.2 (3.4 to 22.2) | 24.2 (16.0 to 34.1) | 7.0 (1.5 to 19.1) | 4.1 (0.9 to 11.5) |
| Swelling: Severe | 0.0 (0.0 to 7.5) | 7.3 (2.7 to 15.2) | 2.4 (0.1 to 12.6) | 1.4 (0.0 to 7.4) |
| Pain: Any | 78.5 (67.8 to 86.9) | 84.8 (78.3 to 89.9) | 83.9 (74.5 to 90.9) | 93.1 (88.2 to 96.4) |
| Pain: Mild | 76.3 (65.2 to 85.3) | 80.1 (73.0 to 86.1) | 81.9 (72.0 to 89.5) | 90.9 (85.4 to 94.8) |
| Pain: Moderate | 24.5 (13.8 to 38.3) | 51.4 (41.7 to 61.0) | 44.1 (31.2 to 57.6) | 53.6 (43.9 to 63.0) |
| Pain: Severe | 2.1 (0.1 to 11.1) | 11.6 (5.7 to 20.3) | 9.1 (2.5 to 21.7) | 5.3 (1.5 to 13.1) |
| Limitation of arm movement: Any | 27.8 (16.5 to 41.6) | 48.2 (38.7 to 57.9) | 42.1 (29.1 to 55.9) | 51.4 (41.6 to 61.1) |
| Limitation of arm movement: Mild | 24.1 (13.5 to 37.6) | 46.4 (36.8 to 56.1) | 40.4 (27.6 to 54.2) | 48.1 (38.3 to 58.0) |
| Limitation of arm movement:Moderate | 4.3 (0.5 to 14.5) | 3.7 (0.8 to 10.4) | 7.0 (1.5 to 19.1) | 9.1 (3.7 to 17.8) |
| Limitation of arm movement: Severe | 2.1 (0.1 to 11.3) | 9.5 (4.2 to 17.9) | 4.9 (0.6 to 16.5) | 5.2 (1.4 to 12.8) |
Systemic events reported using an electronic diary. Systemic events are any fever \>=38 degrees C, fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain, aggravated generalized muscle pain , new generalized joint pain), and aggravated generalized joint pain.
| Percentage of participants | 13vPnC/13vPnC, Cohort 1 | 23vPS/23vPS, Cohort 1 | 13vPnC/23vPS, Cohort 1 | 13vPnC/13vPnC, Cohort 2 |
|---|---|---|---|---|
| Fever >=38 degrees C | 2.1 (0.1 to 11.1) | 2.5 (0.3 to 8.8) | 4.7 (0.6 to 15.8) | 2.7 (0.3 to 9.3) |
| Fever >= 38 to <38.5 degrees C | 0.0 (0.0 to 7.5) | 2.5 (0.3 to 8.8) | 2.4 (0.1 to 12.6) | 2.7 (0.3 to 9.3) |
| Fever >=38.5 to <39 degrees C | 2.1 (0.1 to 11.1) | 0.0 (0.0 to 4.6) | 2.4 (0.1 to 12.6) | 0.0 (0.0 to 4.9) |
| Fever >=39 to =<40 degrees C | 0.0 (0.0 to 7.5) | 0.0 (0.0 to 4.6) | 0.0 (0.0 to 8.6) | 0.0 (0.0 to 4.9) |
| Fever >40 degrees C | 0.0 (0.0 to 7.5) | 0.0 (0.0 to 4.6) | 0.0 (0.0 to 8.6) | 0.0 (0.0 to 4.9) |
| Fatigue | 50.7 (38.4 to 63.03) | 57.6 (48.4 to 66.4) | 63.2 (50.7 to 74.6) | 60.8 (51.7 to 69.4) |
| Headache | 38.3 (26.1 to 51.8) | 54.2 (44.8 to 63.4) | 50.0 (37.2 to 62.8) | 61.8 (52.6 to 70.4) |
| Chills | 23.1 (12.5 to 36.8) | 34.3 (25.1 to 44.6) | 33.9 (21.8 to 47.8) | 25.8 (17.3 to 35.9) |
| Rash | 23.5 (12.8 to 37.5) | 32.6 (23.4 to 43.0) | 18.4 (8.8 to 32.0) | 13.6 (7.0 to 23.0) |
| Vomiting | 8.3 (2.3 to 20.0) | 1.3 (0.0 to 6.9) | 4.7 (0.6 to 15.8) | 3.9 (0.8 to 11.1) |
| Decreased appetite | 21.2 (11.1 to 34.7) | 23.7 (15.5 to 33.6) | 31.5 (19.5 to 45.6) | 24.7 (16.2 to 35.0) |
| New generalized muscle pain | 55.0 (41.6 to 67.9) | 67.6 (59.1 to 75.4) | 65.2 (52.4 to 76.5) | 69.5 (60.8 to 77.4) |
| Aggravated generalized muscle pain | 27.5 (15.9 to 41.7) | 39.6 (30.0 to 49.8) | 41.4 (28.6 to 55.1) | 34.7 (25.3 to 45.2) |
| New generalized joint pain | 18.9 (9.4 to 32.0) | 23.1 (14.9 to 33.1) | 24.5 (13.8 to 38.3) | 33.3 (23.9 to 43.9) |
| Aggravated generalized joint pain | 13.7 (5.7 to 26.3) | 17.6 (10.4 to 27.0) | 22.4 (11.8 to 36.6) | 25.0 (16.4 to 35.4) |
Serotype-specific OPA GMTs for the 13 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using microcolony OPA (mcOPA) assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| titer | 13vPnC, Cohort 1 | 23vPS, Cohort 1 | 13vPnC, Cohort 2 | 13vPnC, Cohort 3 |
|---|---|---|---|---|
| 1 | 146 (124.0 to 172.9) | 104 (87.7 to 124.4) | 200 (170.3 to 236.0) | 353 (322.8 to 386.9) |
| 3 | 93 (81.1 to 106.6) | 85 (74.2 to 98.3) | 91 (79.9 to 104.7) | 91 (84.2 to 98.4) |
| 4 | 2062 (1693.6 to 2510.5) | 1295 (1045.9 to 1603.0) | 2833 (2412.1 to 3327.4) | 4747 (4370.2 to 5155.5) |
| 5 | 199 (164.0 to 242.3) | 162 (133.6 to 197.5) | 269 (218.1 to 332.5) | 386 (342.6 to 435.8) |
| 6A | 2593 (2146.7 to 3131.1) | 213 (160.3 to 284.3) | 4328 (3658.1 to 5121.5) | 5746 (5240.7 to 6300.4) |
| 6B | 1984 (1604.0 to 2453.6) | 788 (615.9 to 1008.5) | 3212 (2728.6 to 3781.4) | 9813 (9097.8 to 10583.5) |
| 7F | 1120 (907.6 to 1382.9) | 405 (311.9 to 524.7) | 1520 (1274.5 to 1812.1) | 3249 (2994.8 to 3523.9) |
| 9V | 1164 (934.8 to 1448.3) | 407 (307.2 to 539.8) | 1726 (1428.5 to 2086.2) | 3339 (3037.4 to 3670.4) |
| 14 | 612 (489.6 to 764.2) | 692 (553.3 to 866.2) | 957 (779.6 to 1174.5) | 2983 (2740.5 to 3246.6) |
| 18C | 1726 (1429.7 to 2082.9) | 925 (735.3 to 1162.9) | 1939 (1599.2 to 2350.2) | 3989 (3629.4 to 4383.8) |
| 19A | 682 (596.5 to 779.9) | 352 (297.0 to 416.1) | 956 (837.6 to 1090.7) | 1580 (1471.4 to 1696.3) |
| 19F | 517 (420.8 to 635.3) | 539 (442.1 to 658.2) | 599 (491.0 to 731.0) | 1533 (1397.3 to 1680.9) |
| 23F | 375 (297.2 to 472.6) | 72 (55.9 to 93.4) | 494 (386.8 to 630.7) | 1570 (1392.8 to 1770.2) |
For serotype 6A the percentage of participants achieving at least a 4-fold rise on the serotype-specific antibody titer from pre-vaccination to 1 month post-vaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.
| percentage of participants | 13vPnC, Cohort 1 | 23vPS, Cohort 1 |
|---|---|---|
| Percentage of Participants Achieving At Least a 4-fold Rise in OPA Titer for Serotype 6A 1 Month After Vaccination 1 in Cohort 1 | 88.5 (84.8 to 91.6) | 49.3 (44.2 to 54.5) |
Serotype-specific OPA GMTs for the 12 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using mcOPA assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| titers | 13vPnC/23vPS, Cohort 1 | 23vPS, Cohort 1 | 23vPs/23vPS, Cohort 1 |
|---|---|---|---|
| 1 | 398 (306.2 to 516.3) | 116 (89.4 to 149.6) | 95 (74.8 to 121.1) |
| 3 | 164 (129.0 to 207.5) | 105 (85.3 to 128.7) | 53 (42.8 to 64.4) |
| 4 | 1875 (1488.8 to 2360.7) | 1420 (1066.2 to 1890.5) | 733 (555.1 to 968.2) |
| 5 | 476 (356.2 to 636.1) | 149 (111.1 to 201.2) | 74 (54.2 to 100.3) |
| 6B | 2670 (2012.9 to 3540.6) | 1088 (774.7 to 1528.1) | 916 (670.0 to 1252.4) |
| 7F | 1895 (1471.0 to 2441.1) | 403 (276.3 to 588.9) | 497 (361.8 to 682.0) |
| 9V | 1089 (699.2 to 1695.0) | 654 (452.5 to 944.9) | 187 (125.0 to 280.3) |
| 14 | 1268 (951.8 to 1690.0) | 824 (612.9 to 1107.8) | 661 (515.6 to 848.6) |
| 18C | 2489 (1941.1 to 3192.7) | 1135 (815.7 to 1578.6) | 802 (597.5 to 1076.8) |
| 19A | 966 (763.2 to 1223.6) | 377 (296.1 to 479.6) | 364 (290.0 to 458.0) |
| 19F | 1653 (1302.2 to 2099.5) | 621 (468.6 to 821.7) | 374 (286.1 to 488.2) |
| 23F | 299 (203.9 to 437.5) | 86 (58.8 to 124.5) | 54 (38.4 to 77.0) |
Percentage of participants achieving OPA GMTs with at least LLOQ for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of all participants using mcOPA assay. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=1:18, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.
| Percentage of participants | 13vPnC, Cohort 1 | 23vPS, Cohort 1 | 13vPnC, Cohort 2 | 13vPnC, Cohort 3 |
|---|---|---|---|---|
| 1 | 90.3 (87.0 to 93.0) | 83.8 (79.9 to 87.3) | 94.0 (91.1 to 96.1) | 97.6 (96.3 to 98.5) |
| 3 | 92.1 (89.0 to 94.6) | 88.3 (84.7 to 91.3) | 92.3 (89.2 to 94.8) | 94.8 (93.1 to 96.2) |
| 4 | 95.0 (92.2 to 97.0) | 91.6 (88.2 to 94.2) | 97.4 (95.2 to 98.8) | 99.2 (98.3 to 99.7) |
| 5 | 87.0 (83.3 to 90.2) | 84.7 (80.8 to 88.1) | 86.1 (82.1 to 89.4) | 92.1 (90.1 to 93.8) |
| 6A | 95.8 (93.3 to 97.5) | 69.1 (64.3 to 73.7) | 97.9 (95.9 to 99.1) | 99.4 (98.6 to 99.8) |
| 6B | 93.5 (90.5 to 95.8) | 86.0 (82.0 to 89.4) | 97.5 (95.3 to 98.9) | 99.9 (99.4 to 100.0) |
| 7F | 90.4 (87.0 to 93.1) | 78.0 (73.6 to 82.0) | 94.7 (91.9 to 96.7) | 98.6 (97.6 to 99.3) |
| 9V | 89.9 (86.4 to 92.8) | 75.8 (71.1 to 80.1) | 93.7 (90.7 to 96.0) | 97.7 (96.5 to 98.6) |
| 14 | 87.7 (84.0 to 90.9) | 88.6 (85.0 to 91.6) | 92.0 (88.7 to 94.5) | 99.0 (98.0 to 99.5) |
| 18C | 95.5 (92.9 to 97.4) | 89.0 (85.4 to 91.9) | 94.9 (92.2 to 96.9) | 98.6 (97.5 to 99.3) |
| 19A | 98.5 (96.7 to 99.4) | 94.3 (91.5 to 96.4) | 98.4 (96.6 to 99.4) | 99.9 (99.4 to 100.0) |
| 19F | 89.7 (86.1 to 92.5) | 90.8 (87.4 to 93.6) | 91.6 (88.2 to 94.2) | 98.1 (96.9 to 98.9) |
| 23F | 84.5 (80.5 to 88.0) | 61.3 (56.2 to 66.3) | 85.1 (81.0 to 88.5) | 95.1 (93.4 to 96.4) |
Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
| Fold Rise | 13vPnC/13vPnC, Cohort 1 | 13vPnC/23vPS, Cohort 1 | 23vPS/23vPS, Cohort 1 | 13vPnC/13vPnC, Cohort 2 |
|---|---|---|---|---|
| 1 | 72.6 (53.90 to 97.82) | 69.7 (51.85 to 93.79) | 15.6 (12.38 to 19.73) | 54.0 (43.92 to 66.50) |
| 3 | 13.2 (9.98 to 17.33) | 21.2 (15.46 to 29.15) | 6.8 (5.49 to 8.54) | 11.5 (9.51 to 13.91) |
| 4 | 68.0 (40.04 to 115.58) | 110.4 (66.47 to 183.22) | 43.8 (27.87 to 68.74) | 104.2 (70.96 to 152.94) |
| 5 | 47.9 (33.51 to 68.52) | 83.2 (60.56 to 114.26) | 11.9 (8.94 to 15.71) | 52.8 (41.81 to 66.71) |
| 6A | 142.0 (84.10 to 239.68) | 116.2 (71.19 to 189.69) | 6.4 (4.25 to 9.53) | 139.7 (93.99 to 207.79) |
| 6B | 103.3 (57.72 to 184.69) | 63.6 (34.73 to 116.29) | 24.9 (15.98 to 38.77) | 132.7 (84.86 to 207.38) |
| 7F | 140.8 (91.49 to 216.59) | 293.9 (203.35 to 424.67) | 72.1 (50.27 to 103.53) | 218.0 (169.33 to 280.62) |
| 9V | 24.7 (12.86 to 47.32) | 40.1 (21.13 to 76.11) | 10.6 (6.52 to 17.13) | 49.9 (32.88 to 75.68) |
| 14 | 20.6 (12.31 to 34.57) | 36.6 (22.02 to 60.97) | 19.9 (13.85 to 28.67) | 26.6 (18.43 to 38.52) |
| 18C | 67.9 (41.02 to 112.48) | 80.9 (48.89 to 133.79) | 27.5 (19.10 to 39.69) | 94.9 (67.89 to 132.54) |
| 19A | 37.6 (25.57 to 55.37) | 43.1 (29.21 to 63.51) | 15.4 (11.79 to 20.25) | 30.9 (23.56 to 40.43) |
| 19F | 54.1 (34.08 to 86.01) | 110.3 (71.30 to 170.65) | 25.1 (18.04 to 34.84) | 60.4 (43.40 to 84.06) |
| 23F | 115.7 (77.40 to 172.81) | 32.5 (21.38 to 49.40) | 6.4 (4.57 to 8.85) | 130.0 (94.64 to 178.44) |
Antibody geometric mean concentration (GMC) as measured by microgram/milliliter (mcg/mL) for 12 common pneumococcal serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
| mcg/mL | 13vPnC/23vPS, Cohort 1 | 23vPS, Cohort 1 | 23vPs/23vPS, Cohort 1 | 13vPnC/13vPnC, Cohort 2 |
|---|---|---|---|---|
| 1 | 9.53 (7.53 to 12.07) | 4.13 (2.86 to 5.96) | 4.36 (3.33 to 5.72) | 6.92 (5.31 to 9.03) |
| 3 | 2.58 (2.14 to 3.11) | 1.88 (1.29 to 2.74) | 1.81 (1.44 to 2.29) | 1.33 (1.07 to 1.64) |
| 4 | 3.68 (2.86 to 4.74) | 1.59 (1.06 to 2.37) | 1.49 (1.14 to 1.95) | 4.89 (3.83 to 6.25) |
| 5 | 11.52 (9.09 to 14.61) | 8.23 (5.81 to 11.67) | 5.78 (4.66 to 7.16) | 7.23 (5.67 to 9.22) |
| 6B | 11.50 (9.21 to 14.37) | 7.81 (5.74 to 10.61) | 5.65 (4.58 to 6.97) | 19.07 (14.59 to 24.92) |
| 7F | 8.52 (6.83 to 10.62) | 8.24 (5.38 to 12.60) | 4.61 (3.57 to 5.95) | 6.26 (5.19 to 7.54) |
| 9V | 7.39 (5.99 to 9.10) | 5.50 (4.15 to 7.30) | 3.78 (3.07 to 4.65) | 4.97 (4.08 to 6.05) |
| 14 | 16.07 (12.31 to 20.98) | 12.05 (7.26 to 19.99) | 8.22 (6.11 to 11.05) | 14.66 (11.97 to 17.96) |
| 18C | 8.56 (6.77 to 10.84) | 8.21 (5.64 to 11.96) | 6.30 (4.70 to 8.45) | 7.17 (5.68 to 9.03) |
| 19A | 14.63 (11.87 to 18.04) | 12.70 (9.29 to 17.37) | 9.88 (7.80 to 12.52) | 16.33 (13.31 to 20.04) |
| 19F | 11.51 (8.64 to 15.34) | 6.42 (4.11 to 10.01) | 3.44 (2.50 to 4.73) | 12.89 (9.75 to 17.06) |
| 23F | 7.11 (5.50 to 9.19) | 4.89 (3.52 to 6.81) | 3.56 (2.81 to 4.52) | 17.20 (13.28 to 22.29) |
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation \[lim\] present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).
| Percentage of participants | 13vPnC, Cohort 1 | 23vPS, Cohort 1 | 13vPnC, Cohort 2 | 13vPnC, Cohort 3 |
|---|---|---|---|---|
| Redness: Any | 20.2 (14.8 to 26.6) | 14.2 (9.6 to 20.0) | 15.8 (10.4 to 22.6) | 30.5 (25.0 to 36.4) |
| Redness: Mild | 15.9 (11.0 to 21.9) | 11.2 (7.1 to 16.7) | 15.2 (9.9 to 22.0) | 26.4 (21.1 to 32.2) |
| Redness: Moderate | 8.6 (5.0 to 13.7) | 4.9 (2.3 to 9.2) | 5.0 (2.0 to 10.0) | 11.9 (8.0 to 16.8) |
| Redness: Severe | 1.7 (0.3 to 4.8) | 0.0 (0.0 to 0.2) | 0.7 (0.0 to 4.0) | 2.8 (1.1 to 6.1) |
| Swelling: Any | 19.3 (14.0 to 25.5) | 13.1 (8.7 to 18.7) | 21.7 (15.6 to 28.9) | 39.4 (33.9 to 45.2) |
| Swelling: Mild | 15.6 (10.8 to 21.5) | 10.1 (6.2 to 15.3) | 20.6 (14.6 to 27.7) | 37.2 (31.7 to 43.0) |
| Swelling: Moderate | 8.2 (4.6 to 13.1) | 4.4 (1.9 to 8.5) | 4.3 (1.6 to 9.2) | 15.1 (10.8 to 20.3) |
| Swelling: Severe | 0.6 (0.0 to 3.1) | 1.1 (0.1 to 4.0) | 0.0 (0.0 to 2.7) | 1.4 (0.3 to 4.1) |
| Pain: Any | 80.1 (75.3 to 84.2) | 73.4 (68.1 to 78.3) | 88.8 (84.9 to 92.0) | 96.7 (95.2 to 97.8) |
| Pain: Mild | 78.6 (73.8 to 83.0) | 68.6 (62.9 to 73.9) | 85.9 (81.5 to 89.6) | 93.2 (91.1 to 94.4) |
| Pain: Moderate | 23.3 (17.7 to 29.7) | 30.0 (23.9 to 36.7) | 39.5 (32.5 to 46.8) | 77.1 (73.0 to 80.8) |
| Pain: Severe | 1.7 (0.3 to 4.8) | 8.6 (5.0 to 13.5) | 3.6 (1.2 to 8.2) | 16.0 (11.6 to 21.3) |
| Lim of arm movement:Any | 28.5 (22.6 to 35.1) | 30.8 (24.6 to 37.5) | 40.7 (33.7 to 48.0) | 75.2 (71.1 to 78.9) |
| Lim of arm movement:Mild | 26.9 (21.0 to 33.4) | 29.3 (23.2 to 36.0) | 38.6 (31.6 to 46.0) | 71.5 (67.1 to 75.5) |
| Lim of arm movement:Moderate | 2.2 (0.6 to 5.6) | 3.8 (1.6 to 7.8) | 2.9 (0.8 to 7.2) | 18.5 (13.8 to 24.0) |
| Lim of arm movement:Severe | 1.7 (0.3 to 4.8) | 4.3 (1.9 to 8.3) | 2.9 (0.8 to 7.2) | 15.6 (11.2 to 20.9) |
Systemic events reported using an electronic diary. Systemic events are any fever greater than or equal to (\>=) 38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized (gen) muscle pain, aggravated generalized muscle pain , new generalized joint pain), and aggravated generalized joint pain. All reports of fever \>40 degrees C in 13vPnC and 23vPS for Cohort 1 were confirmed as data entry errors.
| Percentage of participants | 13vPnC, Cohort 1 | 23vPS, Cohort 1 | 13vPnC, Cohort 2 | 13vPnC, Cohort 3 |
|---|---|---|---|---|
| Fever >=38 degrees C | 7.7 (4.3 to 12.6) | 5.9 (3.0 to 10.4) | 1.5 (0.2 to 5.2) | 7.2 (4.2 to 11.5) |
| Fever >=38 to <38.5 degrees C | 3.9 (1.6 to 7.9) | 1.1 (0.1 to 4.0) | 1.5 (0.2 to 5.2) | 4.2 (1.9 to 7.8) |
| Fever >=38.5 to <39 degrees C | 0.6 (0.0 to 3.1) | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.7) | 1.9 (0.5 to 4.8) |
| Fever >=39 to =<40 degrees C | 0.0 (0.0 to 2.1) | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.7) | 1.4 (0.3 to 4.1) |
| Fever >40 degrees C | 4.4 (1.9 to 8.6) | 4.9 (2.3 to 9.1) | 0.0 (0.0 to 2.7) | 0.5 (0.0 to 2.6) |
| Fatigue | 63.2 (57.2 to 68.9) | 61.5 (55.5 to 67.3) | 63.3 (57.0 to 69.3) | 80.5 (77.0 to 83.7) |
| Headache | 54.0 (47.6 to 60.2) | 54.4 (48.2 to 60.6) | 65.9 (59.6 to 71.8) | 81.4 (77.8 to 84.6) |
| Chills | 23.5 (17.9 to 30.0) | 24.1 (18.4 to 30.7) | 19.6 (13.7 to 26.7) | 38.1 (32.5 to 44.0) |
| Rash | 16.5 (11.6 to 22.5) | 13.0 (8.6 to 18.6) | 14.2 (9.0 to 20.9) | 21.3 (16.4 to 26.9) |
| Vomiting | 3.9 (1.6 to 7.8) | 5.4 (2.6 to 9.7) | 6.9 (3.4 to 12.4) | 15.0 (10.7 to 20.2) |
| Decreased appetite | 21.3 (15.9 to 27.6) | 21.7 (16.3 to 28.0) | 25.3 (18.9 to 32.6) | 55.6 (50.4 to 60.8) |
| New gen muscle pain | 56.2 (49.8 to 62.5) | 57.8 (51.7 to 63.8) | 61.8 (55.3 to 68.0) | 82.0 (78.6 to 85.1) |
| Aggravated gen muscle pain | 32.6 (26.3 to 39.3) | 37.3 (31.0 to 44.0) | 39.9 (32.8 to 47.3) | 55.9 (50.7 to 61.1) |
| New gen joint pain | 24.4 (18.5 to 31.0) | 30.1 (24.1 to 36.7) | 31.5 (24.5 to 39.2) | 41.7 (36.1 to 47.4) |
| Aggravated gen joint pain | 24.9 (19.1 to 31.4) | 21.4 (16.0 to 27.6) | 25.6 (19.2 to 32.9) | 28.6 (23.3 to 34.4) |
Collected over Adverse events collected after vaccination and at the 6-month follow-up contact. Participants recorded pre-specified AEs in electronic diary: local reactions and systemic events from Day 1-Day 14 post vaccination.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC, Cohort 1 | — | 1/417 (0.2%) | 277/417 (66.4%) |
| 13vPnC: 6 Month Follow-up After Vax 1, Cohort 1 | — | 12/417 (2.9%) | 0/417 (0%) |
| 23vPS, Cohort 1 | — | 2/414 (0.5%) | 271/414 (65.5%) |
| 23vPS: 6 Month Follow-up After Vax 1, Cohort 1 | — | 10/414 (2.4%) | 5/414 (1.2%) |
| 13vPnC, Cohort 2 | — | 2/403 (0.5%) | 293/403 (72.7%) |
| 13vPnC: 6 Month Follow-up After Vax 1, Cohort 2 | — | 5/403 (1.2%) | 2/403 (0.5%) |
| 13vPnC/13vPnC, Cohort 1 | — | 1/108 (0.9%) | 66/108 (61.1%) |
| 13vPnC/13vPnC: 6 Month Follow-up After Vax 2, Cohort 1 | — | 2/108 (1.9%) | 1/108 (0.9%) |
| 13vPnC/23vPS, Cohort 1 | — | 1/108 (0.9%) | 73/108 (67.6%) |
| 13vPnC/23vPS: 6 Month Follow-up After Vax 2, Cohort 1 | — | 1/108 (0.9%) | 4/108 (3.7%) |
| 23vPS/23vPS, Cohort 1 | — | 0/189 (0%) | 143/189 (75.7%) |
| 23vPS/23vPS: 6 Month Follow-up After Vax 2, Cohort 1 | — | 3/189 (1.6%) | 13/189 (6.9%) |
| 13vPnC/13vPnC, Cohort 2 | — | 0/214 (0%) | 164/214 (76.6%) |
| 13vPnC/13vPnC: 6 Month Follow-up After Vax 2, Cohort 2 | — | 0/214 (0%) | 4/214 (1.9%) |
| 13vPnC, Cohort 3 | — | 2/899 (0.2%) | 779/899 (86.7%) |
| 13vPnC: 6 Month Follow-up After Vax 1, Cohort 3 | — | 2/899 (0.2%) | 1/899 (0.1%) |
| Event | 13vPnC, Cohort 1 | 13vPnC: 6 Month Follow-up After Vax 1, Cohort 1 | 23vPS, Cohort 1 | 23vPS: 6 Month Follow-up After Vax 1, Cohort 1 | 13vPnC, Cohort 2 | 13vPnC: 6 Month Follow-up After Vax 1, Cohort 2 | 13vPnC/13vPnC, Cohort 1 | 13vPnC/13vPnC: 6 Month Follow-up After Vax 2, Cohort 1 | 13vPnC/23vPS, Cohort 1 | 13vPnC/23vPS: 6 Month Follow-up After Vax 2, Cohort 1 | 23vPS/23vPS, Cohort 1 | 23vPS/23vPS: 6 Month Follow-up After Vax 2, Cohort 1 | 13vPnC/13vPnC, Cohort 2 | 13vPnC/13vPnC: 6 Month Follow-up After Vax 2, Cohort 2 | 13vPnC, Cohort 3 | 13vPnC: 6 Month Follow-up After Vax 1, Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ligament ruptureInjury, poisoning and procedural complications | 0/417 | 0/417 | 0/414 | 0/414 | 0/403 | 0/403 | 0/108 | 0/108 | 1/108 | 0/108 | 0/189 | 0/189 | 0/214 | 0/214 | 0/899 | 0/899 |
| Erythema multiformeSkin and subcutaneous tissue disorders | 0/417 | 0/417 | 0/414 | 0/414 | 0/403 | 0/403 | 1/108 | 0/108 | 0/108 | 0/108 | 0/189 | 0/189 | 0/214 | 0/214 | 0/899 | 0/899 |
| Coronary artery diseaseCardiac disorders | 0/417 | 1/417 | 0/414 | 0/414 | 0/403 | 0/403 | 0/108 | 1/108 | 0/108 | 0/108 | 0/189 | 0/189 | 0/214 | 0/214 | 0/899 | 0/899 |
| PneumoniaInfections and infestations | 0/417 | 1/417 | 0/414 | 0/414 | 0/403 | 0/403 | 0/108 | 0/108 | 0/108 | 1/108 | 0/189 | 0/189 | 0/214 | 0/214 | 0/899 | 0/899 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/417 | 1/417 | 0/414 | 0/414 | 0/403 | 0/403 | 0/108 | 1/108 | 0/108 | 0/108 | 0/189 | 0/189 | 0/214 | 0/214 | 0/899 | 0/899 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 0/417 | 0/417 | 0/414 | 0/414 | 0/403 | 0/403 | 0/108 | 0/108 | 0/108 | 0/108 | 0/189 | 1/189 | 0/214 | 0/214 | 0/899 | 0/899 |
| Rib fractureInjury, poisoning and procedural complications | 0/417 | 0/417 | 0/414 | 0/414 | 0/403 | 0/403 | 0/108 | 0/108 | 0/108 | 0/108 | 0/189 | 1/189 | 0/214 | 0/214 | 0/899 | 0/899 |
| Endometrial cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/417 | 0/417 | 0/414 | 0/414 | 0/403 | 0/403 | 0/108 | 0/108 | 0/108 | 0/108 | 0/189 | 1/189 | 0/214 | 0/214 | 0/899 | 0/899 |
| NystagmusNervous system disorders | 0/417 | 0/417 | 0/414 | 0/414 | 0/403 | 0/403 | 0/108 | 0/108 | 0/108 | 0/108 | 0/189 | 1/189 | 0/214 | 0/214 | 0/899 | 0/899 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/417 | 1/417 | 0/414 | 2/414 | 0/403 | 0/403 | 0/108 | 0/108 | 0/108 | 0/108 | 0/189 | 0/189 | 0/214 | 0/214 | 0/899 | 0/899 |
| Event | 13vPnC, Cohort 1 | 13vPnC: 6 Month Follow-up After Vax 1, Cohort 1 | 23vPS, Cohort 1 | 23vPS: 6 Month Follow-up After Vax 1, Cohort 1 | 13vPnC, Cohort 2 | 13vPnC: 6 Month Follow-up After Vax 1, Cohort 2 | 13vPnC/13vPnC, Cohort 1 | 13vPnC/13vPnC: 6 Month Follow-up After Vax 2, Cohort 1 | 13vPnC/23vPS, Cohort 1 | 13vPnC/23vPS: 6 Month Follow-up After Vax 2, Cohort 1 | 23vPS/23vPS, Cohort 1 | 23vPS/23vPS: 6 Month Follow-up After Vax 2, Cohort 1 | 13vPnC/13vPnC, Cohort 2 | 13vPnC/13vPnC: 6 Month Follow-up After Vax 2, Cohort 2 | 13vPnC, Cohort 3 | 13vPnC: 6 Month Follow-up After Vax 1, Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pain (Any)Skin and subcutaneous tissue disorders | 265/331 | — | 221/301 | — | 286/322 | — | 62/79 | — | 73/87 | — | 139/164 | — | 161/173 | — | 761/787 | 0/899 |
| Pain (Mild)Skin and subcutaneous tissue disorders | 254/323 | — | 199/290 | — | 263/306 | — | 58/76 | — | 68/83 | — | 125/156 | — | 150/165 | — | 672/721 | 0/899 |
| New generalized muscle painGeneral disorders | 140/249 | — | 155/268 | — | 147/238 | — | 33/60 | — | 43/66 | — | 92/136 | — | 89/128 | — | 460/561 | 0/899 |
| HeadacheGeneral disorders | 136/252 | — | 141/259 | — | 162/246 | — | 23/60 | — | 32/64 | — | 64/118 | — | 76/123 | — | 429/527 | 0/899 |
| FatigueGeneral disorders | 175/277 | — | 168/273 | — | 157/248 | — | 35/69 | — | 43/68 | — | 72/125 | — | 76/125 | — | 446/554 | 0/899 |
| Pain (Moderate)Skin and subcutaneous tissue disorders | 48/206 | — | 63/210 | — | 75/190 | — | 13/53 | — | 26/59 | — | 57/111 | — | 60/112 | — | 360/467 | 0/899 |
| Limitation of arm movement (Any)Skin and subcutaneous tissue disorders | 61/214 | — | 65/211 | — | 79/194 | — | 15/54 | — | 24/57 | — | 54/112 | — | 56/109 | — | 375/499 | 0/899 |
| Limitation of arm movement (Mild)Skin and subcutaneous tissue disorders | 57/212 | — | 61/208 | — | 73/189 | — | 13/54 | — | 23/57 | — | 51/110 | — | 51/106 | — | 333/466 | 0/899 |
| Aggravated generalized muscle painGeneral disorders | 70/215 | — | 84/225 | — | 75/188 | — | 14/51 | — | 24/58 | — | 40/101 | — | 33/95 | — | 207/370 | 0/899 |
| Decreased appetiteGeneral disorders | 43/202 | — | 45/207 | — | 42/166 | — | 11/52 | — | 17/54 | — | 22/93 | — | 22/89 | — | 202/363 | 0/899 |
| Age, Customized(participants) | 13vPnC, Cohort 1 | 23vPS, Cohort 1 | 13vPnC, Cohort 2 | 13vPnC, Cohort 3 | Total |
|---|---|---|---|---|---|
| 18 to 29 years | 0 | 0 | 0 | 300 | 300 |
| 30 to 39 years | 0 | 0 | 0 | 298 | 298 |
| 40 to 49 years | 0 | 0 | 0 | 301 | 301 |
| 50 to 59 years | 0 | 0 | 403 | 0 | 403 |
| 60 to 64 years | 417 | 414 | 0 | 0 | 831 |
| Sex: Female, Male(Participants) | 13vPnC, Cohort 1 | 23vPS, Cohort 1 | 13vPnC, Cohort 2 | 13vPnC, Cohort 3 | Total |
|---|---|---|---|---|---|
| Female | 223 | 252 | 249 | 523 | 1247 |
| Male | 194 | 162 | 154 | 376 | 886 |
Ran from Feb 2007 to primary completion in Aug 2011, 53 months.
Results were first posted in Sep 2012, 1 year 1 month after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 53 months is above that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine